Theseus Pharmaceuticals Cash Flow Statement

Financials in millions BDT. Fiscal year is January - December.

Millions BDT. Fiscal year is Jan - Dec.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020	2016 - 2020
Period Ending	Jun '25 Jun 30, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021	Dec '20 Dec 31, 2020	2016 - 2020
Net Income	2.93	2.93	120.63	263.14	261.29	321.39	Upgrade
Depreciation & Amortization	15.3	15.3	15.75	17.48	19.63	19.41	Upgrade
Change in Trading Asset Securities	-	-	-	-	206.59	-	Upgrade
Change in Other Net Operating Assets	-1,593	-2,881	2,770	-2,468	598.26	152.61	Upgrade
Other Operating Activities	221.38	326.1	42.99	-55.49	-8.34	98.6	Upgrade
Operating Cash Flow	-1,354	-2,536	2,950	-2,242	1,077	592.01	Upgrade
Operating Cash Flow Growth	-	-	-	-	82.00%	-	Upgrade
Capital Expenditures	-1.65	-1.94	-3	-4.04	-11.52	-25.2	Upgrade
Investment in Securities	-45.36	-295.76	-350.46	-478.04	-21.37	-666.66	Upgrade
Investing Cash Flow	-47.01	-297.7	-353.46	-482.08	-32.89	-691.86	Upgrade
Long-Term Debt Issued	-	371.23	-	1,264	32.46	-	Upgrade
Long-Term Debt Repaid	-	-	-443.08	-	-	-779.75	Upgrade
Net Debt Issued (Repaid)	-139.15	371.23	-443.08	1,264	32.46	-779.75	Upgrade
Common Dividends Paid	-117.03	-117.03	-175.55	-175.55	-175.55	-117.03	Upgrade
Financing Cash Flow	-256.19	254.2	-618.62	1,089	-143.09	-896.78	Upgrade
Net Cash Flow	-1,657	-2,580	1,978	-1,636	901.45	-996.63	Upgrade
Free Cash Flow	-1,355	-2,538	2,947	-2,247	1,066	566.81	Upgrade
Free Cash Flow Growth	-	-	-	-	88.06%	-	Upgrade
Free Cash Flow Margin	-533.69%	-833.88%	792.22%	-345.80%	166.99%	84.64%	Upgrade
Free Cash Flow Per Share	-11.57	-21.69	25.18	-19.20	9.11	4.84	Upgrade
Cash Interest Paid	1,362	1,362	999.12	984.95	1,046	1,433	Upgrade
Cash Income Tax Paid	98.28	98.28	153.65	168.33	186.18	129.34	Upgrade

Updated Nov 11, 2024. Source: S&P Global Market Intelligence. Financial Services template. Financial Sources.